---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-411259"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2026-10-02T11:30:19+00:00"
generated_at: "2026-10-12T14:30:52.974222+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Cerenome files Sept 30 investor deck; exhibit has no financials, pipeline data or guidance

## Summary
- Investor presentation dated September 30, 2026 was filed as Exhibit 99.1, but the appended text contains only a title page ('Corporate Presentation (NASDAQ:CNSY)') with no numbers or outlook.
- No earnings, revenue, cash balance, trial data or guidance is disclosed anywhere in the 8-K or its exhibit, so no investment conclusions can be drawn from this filing.
- Registrant is Cerenome, Inc., formerly Plus Therapeutics, Inc., with common stock on the Nasdaq Capital Market under symbol CNSY and offices at 6420 Levit Green Boulevard, Suite 310, Houston, Texas.
- Report signed October 2, 2026 by President and Chief Executive Officer Marc H. Hedrick, M.D.; Item 8.01 lists only the presentation update as the event.

## SEC filing metadata
- accession: 0001193125-26-411259
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2026-10-02T11:30:19+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312526411259/0001193125-26-411259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312526411259/cnsy-20261002.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-411259
- JSON: https://secwatch.observer/filing/0001193125-26-411259.json
- Plain text: https://secwatch.observer/filing/0001193125-26-411259.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.